StockNews.com Begins Coverage on Fresenius Medical Care (NYSE:FMS)

StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Tuesday. The brokerage issued a strong-buy rating on the stock.

Separately, Truist Financial raised their price target on shares of Fresenius Medical Care from $21.00 to $24.00 and gave the company a hold rating in a research report on Wednesday, May 15th. One research analyst has rated the stock with a sell rating, four have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Hold and a consensus target price of $32.25.

Fresenius Medical Care Trading Up 0.4 %

NYSE:FMS opened at $19.17 on Tuesday. The firm has a 50 day moving average of $20.84 and a 200 day moving average of $20.21. The stock has a market capitalization of $11.25 billion, a price-to-earnings ratio of 21.54, a PEG ratio of 1.02 and a beta of 0.93. Fresenius Medical Care has a 52 week low of $16.37 and a 52 week high of $27.72. The company has a quick ratio of 1.14, a current ratio of 1.50 and a debt-to-equity ratio of 0.46.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.26 by $0.10. The company had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.15 billion. Fresenius Medical Care had a net margin of 2.48% and a return on equity of 5.29%. As a group, sell-side analysts anticipate that Fresenius Medical Care will post 1.5 earnings per share for the current fiscal year.

Fresenius Medical Care Cuts Dividend

The business also recently announced an annual dividend, which was paid on Monday, June 3rd. Stockholders of record on Monday, May 20th were given a $0.437 dividend. The ex-dividend date of this dividend was Friday, May 17th. This represents a dividend yield of 2.35%. Fresenius Medical Care’s dividend payout ratio (DPR) is 49.44%.

Institutional Trading of Fresenius Medical Care

Several institutional investors have recently modified their holdings of the stock. Bruce G. Allen Investments LLC purchased a new position in shares of Fresenius Medical Care in the fourth quarter worth about $31,000. Hartford Financial Management Inc. lifted its stake in shares of Fresenius Medical Care by 98.8% in the fourth quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company’s stock worth $35,000 after buying an additional 839 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Fresenius Medical Care by 349.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,314 shares of the company’s stock worth $48,000 after buying an additional 1,799 shares in the last quarter. GAMMA Investing LLC purchased a new position in shares of Fresenius Medical Care in the fourth quarter worth about $67,000. Finally, Assetmark Inc. lifted its stake in shares of Fresenius Medical Care by 169.9% in the fourth quarter. Assetmark Inc. now owns 4,178 shares of the company’s stock worth $87,000 after buying an additional 2,630 shares in the last quarter. Institutional investors and hedge funds own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.